In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Centogene NV (CNTG – Research Report), with a price target of $2.50. The company’s shares closed last Friday at $1.03.
According to TipRanks, Chen is an analyst with an average return of -9.5% and a 33.73% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vaccitech Plc, Veru, and Prophase Labs.
Centogene NV has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.
See Insiders’ Hot Stocks on TipRanks >>
CNTG market cap is currently $23.25M and has a P/E ratio of -0.37.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Read More on CNTG:
- Twist Centogene launch target enrichment panels for rare disease diagnosis
- Centogene, Denali extend observational study on Parkinson’s disease genetics
- Centogene, Premier Research announce strategic partnership
- CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco
- CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
